India, June 11 -- Shares of Kazia Therapeutics Limited (KZIA) more than doubled after the clinical-stage biotechnology company announced transformative preclinical data demonstrating Paxalisib's potential to overcome immunotherapy resistance in Triple-Negative Breast Cancer (TNBC).
KZIA is currently trading at $10.57, up $5.32 or 101.15%, on a huge volume of 30 million shares, above average volume of 28 thousand, on the Nasdaq. The stock opened its trading at $10.50 after closing Tuesday at $5.26. The stock has traded between $2.86 and $79.00 in the past 52-week period.
Kazia Therapeutics announced the publication of transformative preclinical research in the journal Molecular Cancer Therapeutics, a journal of the American Association for...